PE20090299A1 - Antagonistas cxcr4 de peptido ciclicos - Google Patents

Antagonistas cxcr4 de peptido ciclicos

Info

Publication number
PE20090299A1
PE20090299A1 PE2008000868A PE2008000868A PE20090299A1 PE 20090299 A1 PE20090299 A1 PE 20090299A1 PE 2008000868 A PE2008000868 A PE 2008000868A PE 2008000868 A PE2008000868 A PE 2008000868A PE 20090299 A1 PE20090299 A1 PE 20090299A1
Authority
PE
Peru
Prior art keywords
lys
glu
cxcr4 antagonists
naphthylalanine
gly
Prior art date
Application number
PE2008000868A
Other languages
English (en)
Inventor
Wayne David Kohn
Sheng-Bin Peng
Liang Zeng Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831600&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20090299A1 publication Critical patent/PE20090299A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN PEPTIDO CICLIZADO POR LACTAMAS DE FORMULA (I), DONDE LA LACTAMA SE FORMA POR UN ENLACE AMIDA ENTRE EL GRUPO AMINO DE CADENA LATERAL DE X1 Y EL GRUPO CARBOXILO DE CADENA LATERAL DE X7; X1 Y X7 SON (D/L)Agl/Glu, Dab/Glu O Dap/Glu; R1 ESTA AUSENTE O ES ACETILO, BENZOILO O n-HEXANOILO; X1 ES Ala, 5-AMINOVALERILO, 4-ACIDO AMINO METILO, Asp, ENTRE OTROS; X3 ES Arg, Lys, Lys(iPr), Lys(Me2); X7 ES Asp, ACIDO 2,4-DIAMINOBUTIRICO, ACIDO 2,3-DIAMINO-PROPIONICO, ENTRE OTROS; X8 ES Arg, Gly, Lys, Orn, ENTRE OTROS; X9 ES Gly, 2-NAFTILALANINA, ENTRE OTROS; X10 ES 2-NAFTILALANINA O ESTA AUSENTE; R2 ES NH2 O NHEt. DICHOS COMPUESTOS SON ANTAGONISTAS CXCR4 Y SON UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATICA, FIBROSIS PULMONAR, INFECCION POR VIH, ENTRE OTROS
PE2008000868A 2007-05-30 2008-05-20 Antagonistas cxcr4 de peptido ciclicos PE20090299A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94080207P 2007-05-30 2007-05-30
US94099607P 2007-05-31 2007-05-31

Publications (1)

Publication Number Publication Date
PE20090299A1 true PE20090299A1 (es) 2009-03-19

Family

ID=39831600

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000868A PE20090299A1 (es) 2007-05-30 2008-05-20 Antagonistas cxcr4 de peptido ciclicos

Country Status (33)

Country Link
US (3) US7691813B2 (es)
EP (2) EP2160221B1 (es)
JP (1) JP5358564B2 (es)
KR (2) KR101319740B1 (es)
CN (1) CN101678213B (es)
AR (1) AR066648A1 (es)
AT (1) ATE516853T1 (es)
AU (1) AU2008260326B2 (es)
BR (1) BRPI0812134A2 (es)
CA (1) CA2688574C (es)
CL (1) CL2008001467A1 (es)
CO (1) CO6241137A2 (es)
CR (1) CR11105A (es)
CY (1) CY1111815T1 (es)
DK (1) DK2160221T3 (es)
DO (1) DOP2009000270A (es)
EA (1) EA017716B1 (es)
GT (1) GT200900304A (es)
HK (1) HK1141474A1 (es)
HR (1) HRP20110551T1 (es)
IL (1) IL201685A (es)
JO (1) JO2776B1 (es)
MA (1) MA31666B1 (es)
MX (1) MX2009012952A (es)
MY (1) MY149432A (es)
NZ (1) NZ580849A (es)
PE (1) PE20090299A1 (es)
PL (1) PL2160221T3 (es)
PT (1) PT2160221E (es)
TN (1) TN2009000496A1 (es)
TW (1) TWI423987B (es)
WO (1) WO2008150689A1 (es)
ZA (1) ZA200908345B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2942798B1 (fr) 2009-03-05 2011-04-08 Centre Nat Rech Scient Peptides utilisables pour le traitement de la leucemie lymphoide chronique
IT1397901B1 (it) 2010-01-26 2013-02-04 Consiglio Nazionale Ricerche Peptidi ciclici che legano il recettore cxcr4 e relativi usi in campo medico e diagnostico.
WO2012118124A1 (ja) * 2011-03-01 2012-09-07 国立大学法人京都大学 新規ケモカイン受容体拮抗剤
CN103703018B (zh) * 2011-06-07 2016-10-26 波利弗尔股份公司 作为CXC4拮抗剂的β-发夹肽模拟物
WO2013044500A1 (zh) * 2011-09-30 2013-04-04 Cheng Yun 丙型肝炎病毒免疫原性肽或其衍生物在预防或治疗关节炎中的应用
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
EP2979991A1 (en) 2014-07-31 2016-02-03 Greif International Holding BV. Multilayer material, fire protection mat with said multilayer material and transport and storage container assembly comprising said fire protection mat.
EP3050574B1 (en) 2015-01-28 2019-10-09 Universite De Bordeaux Use of plerixafor for treating and/or preventing acute exacerbations of chronic obstructive pulmonary disease
WO2017176565A1 (en) 2016-04-07 2017-10-12 Eli Lilly And Company Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor
JP7100639B2 (ja) * 2016-09-06 2022-07-13 メインライン バイオサエンシズ Ｃｘｃｒ４アンタゴニストおよび使用方法
CN106841624B (zh) * 2017-01-26 2019-02-22 庄磊靓 抗人cd4和抗人cd184单克隆抗体作为标志物的应用
US11123437B2 (en) * 2017-09-05 2021-09-21 Mainline Biosciences, Inc. Selective CXCR4 binding peptide conjugate and methods for making and using the same
EP3679053A4 (en) * 2017-09-05 2021-10-27 Mainline Biosciences CXCR4 SELECTIVE BINDING CONJUGATE WITH HIGH AFFINITY AND METHOD OF USE
US11771736B2 (en) * 2017-12-21 2023-10-03 Mainline Biosciences (Shanghai) Co., Ltd. Composition comprising a therapeutic agent and a CXCR4 selective antagonist and methods for using the same
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
CN112673015A (zh) 2018-09-12 2021-04-16 慕尼黑工业大学 具有降低的物种选择性的cxcr4靶向诊断和治疗剂
WO2020053255A1 (en) 2018-09-12 2020-03-19 Technische Universität München Therapeutic and diagnostic agents for cancer
EP3956346A4 (en) * 2019-04-18 2023-01-18 Provincial Health Services Authority NEW RADIOLABALED DIAGNOSTIC AND THERAPEUTIC COMPOUNDS TARGETING CXCR4
WO2021150258A1 (en) * 2020-01-26 2021-07-29 Mainline Biosciences Llc Isotopically labelled selective cxcr4 binding peptide conjugate and methods for making and using the same
EP4269422A1 (en) * 2020-12-25 2023-11-01 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound containing n-substituted-amino acid residue
EP4043041A1 (en) 2021-02-15 2022-08-17 Technische Universität München Cxcr4-ligands for diagnostic and therapeutic use and precursors thereof
WO2023201435A1 (en) * 2022-04-20 2023-10-26 Provincial Health Services Authority Cxcr4-targeting compounds, and methods of making and using the same
CN115060901A (zh) * 2022-06-21 2022-09-16 中国医学科学院基础医学研究所 苹果酸酶2在制备矽肺病或肺纤维化相关疾病诊断试剂或治疗药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4391123B2 (ja) * 2002-10-24 2009-12-24 株式会社オーファンリンク 新規ｃｘｃｒ４アンタゴニスト
CA2643744A1 (en) * 2006-02-27 2007-08-30 Technische Universitaet Muenchen Cancer imaging and treatment

Also Published As

Publication number Publication date
EA017716B1 (ru) 2013-02-28
IL201685A (en) 2015-04-30
KR101169846B1 (ko) 2012-08-01
MX2009012952A (es) 2009-12-11
PL2160221T3 (pl) 2011-12-30
HRP20110551T1 (hr) 2011-09-30
DK2160221T3 (da) 2011-09-19
EP2377579A1 (en) 2011-10-19
WO2008150689A1 (en) 2008-12-11
ATE516853T1 (de) 2011-08-15
TWI423987B (zh) 2014-01-21
AU2008260326A1 (en) 2008-12-11
MA31666B1 (fr) 2010-09-01
TW200902556A (en) 2009-01-16
TN2009000496A1 (en) 2011-03-31
KR101319740B1 (ko) 2013-10-17
AR066648A1 (es) 2009-09-02
CN101678213B (zh) 2013-11-06
CA2688574C (en) 2014-02-18
EA200971129A1 (ru) 2010-04-30
EP2160221B1 (en) 2011-07-20
KR20100003737A (ko) 2010-01-11
KR20110134519A (ko) 2011-12-14
ZA200908345B (en) 2011-02-23
US7691813B2 (en) 2010-04-06
CR11105A (es) 2010-04-12
CN101678213A (zh) 2010-03-24
CO6241137A2 (es) 2011-01-20
NZ580849A (en) 2012-03-30
DOP2009000270A (es) 2010-01-15
IL201685A0 (en) 2010-05-31
US20080300177A1 (en) 2008-12-04
EP2160221A1 (en) 2010-03-10
JO2776B1 (en) 2014-03-15
GT200900304A (es) 2011-11-09
US20100130409A1 (en) 2010-05-27
PT2160221E (pt) 2011-09-12
JP5358564B2 (ja) 2013-12-04
USRE42274E1 (en) 2011-04-05
CL2008001467A1 (es) 2008-12-05
MY149432A (en) 2013-08-30
AU2008260326B2 (en) 2011-07-21
CY1111815T1 (el) 2015-10-07
CA2688574A1 (en) 2008-12-11
JP2010529957A (ja) 2010-09-02
HK1141474A1 (en) 2010-11-12
BRPI0812134A2 (pt) 2014-11-18

Similar Documents

Publication Publication Date Title
PE20090299A1 (es) Antagonistas cxcr4 de peptido ciclicos
ES2566830T3 (es) Péptido capaz de extender la semivida de péptido de interés en plasma
ES2548767T3 (es) Nuevos péptidos antimicrobianos
JP2010529957A5 (es)
PE20140159A1 (es) Coagonistas del receptor de glucagon/glp-1
CY1113115T1 (el) Πεπτιδια - αναστολεις συντηξης του ηiv με βελτιωμενες βιολογικες ιδιοτητες
DE69938064D1 (de) Aminoterminal modifizierte parathyroidhormon (pth) analoge
UA100127C2 (ru) Пептид cdh3 и лекарственное средство, содержащее его
Lohani et al. Solid-phase synthesis and in vitro biological activity of a Thr4→ Ser4 analog of daptomycin
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
HUP0300917A2 (hu) Bradikardiakumok alkalmazása hipertrófiával társult miokardiális betegségek kezelésére és ezeket tartalmazó gyógyszerkészítmények
MXPA02000465A (es) Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6.
Tamamura et al. Downsizing of an HIV–cell fusion inhibitor, T22 ([Tyr5, 12, Lys7]-Polyphemusin II), with the maintenance of anti-HIV activity and solution structure1
JPWO2021070696A5 (es)
Koizumi et al. Structure–activity relationship of cyclic pentapeptide malformins as fibrinolysis enhancers
HUP0301396A2 (hu) Integrin inhibitor hatású peptid- és peptidutánzó konjugátumok, azokat tartalmazó implantátumok és alkalmazásuk
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
AU2016232361B2 (en) Cyclic galanin-analogs and uses thereof
WO2007125142A8 (es) Péptidos lineales antimicrobianos
Lee et al. Synthesis and structure-function study about tenecin 1, an antibacterial protein from larvae of Tenebrio molitor
WO2008070049A8 (en) Peptide and treatment for hiv-1 infection
NO20052525L (no) Spleisevariant av humant hypofyseveksthormon
ATE529440T1 (de) Biologisch aktives peptid und wirkstoff, der dieses enthält
Kanumuri et al. Increased yield of high purity recombinant human brain natriuretic peptide by acid hydrolysis of short fusion partner in Escherichia coli
RS51950B (en) CYCLIC PEPTIDE ANTAGONISTS CXCR4

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed